RecruitingPhase 1NCT07362888

First-in-Human Study of ADCE-B05 in Patients With Advanced Solid Tumors

A First-in-Human, Phase 1a/1b, Open-Label Multicenter Study to Assess the Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Antitumor Activity of the Antibody Drug Conjugate ADCE-B05 in Patients With Advanced Solid Tumors

Sponsor

Adcendo ApS

Enrollment

180 participants

Start Date

Mar 17, 2026

Study Type

INTERVENTIONAL

Conditions

Solid Tumors (Phase 1)

Summary

The main purpose of the study is to determine the Maximum Tolerated Dose (MTD), the Recommended Expansion Dose and the safety and tolerability of ADCE-B05 when given as a single therapy over a range of different dose levels.

Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a drug called ADCE-B05 for people with solid tumors (phase 1). The study is currently recruiting participants at 7 locations. People eligible for this study include aged 18 Years and older.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGADCE-B05

Biological: Antibody-drug conjugate (ADC)

Locations(7)

Highlands Oncology Group

Springdale, Arkansas, United States

Yale University

New Haven, Connecticut, United States

University Of Texas MD Anderson Cancer Center

Houston, Texas, United States

Scientia Clinical Research

Randwick, New South Wales, Australia

Southern Oncology Clinical Research Unit

Bedford Park, South Australia, Australia

Monash Health

Clayton, Victoria, Australia

Peter MacCallum Cancer Centre

Melbourne, Victoria, Australia

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT07362888

Related Trials

Evaluation of RAS Inhibitor Treatment in Participants With Advanced or Metastatic Solid Tumors Harboring RAS Mutations

NCT072524793 locations

Phase I Study of HSK42360-Na in Solid Tumors With BRAF V600 Mutation

NCT075615542 locations

A Early Study of ABSK131 in Patients With Advanced/Metastatic Solid Tumors

NCT072889571 location

A Phase 1/1b of RNDO-564 Single Agent or in Combination With Pembrolizumab in Bladder Cancer and Other Solid Tumors Associated With Nectin-4

NCT072180032 locations